Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PInNACLe: Nilotinib and Pegylated Interferon in CML
NCT02001818Phase 2Completed
- Sponsor
- Australasian Leukaemia & Lymphoma Group
- Start
- Apr 2014
- Primary completion
- Jan 2022
- Modality
- Polymer-based Nanoparticles, Cytokines & Interferons
- Countries
- 1
01
Overview
A Phase 2 trial of peginterferon alfa-2b in chronic myeloid leukemia (CML), sponsored by Australasian Leukaemia & Lymphoma Group. Started Apr 2014; status: completed.
02
Drugs
peginterferon alfa-2b
03
Conditions
chronic myeloid leukemia (CML)
Beyond the preview
Go deeper on NCT02001818.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT02001818.